Medications
Reached your goal weight? How to reduce your dose without regaining
A lower dose can hold most weight loss. How the maintenance phase works, and how to plan dose reduction with your doctor.
Well Revolution
August 26, 2026
What the new maintenance evidence shows, and how to plan the step down with your doctor
For years, people on weight loss injections faced an uncomfortable question at their goal weight: is it maximum dose forever, or stop and watch the weight return? Clinicians quietly knew there was a middle path, because they were using it, but there was no trial to point to.
Now there is. And it says the middle path works.
The evidence: maintenance is a real phase
The SURMOUNT-MAINTAIN trial, published in The Lancet in May 2026, is the first randomised trial built specifically to test weight maintenance strategies. People with obesity took tirzepatide for 60 weeks, reaching their maximum tolerated dose (10 or 15 mg weekly). Then they were randomised three ways: continue the full dose, drop to a low 5 mg maintenance dose, or switch to placebo.
A year later:
- Full dose: still 21.9 percent below their original starting weight.
- Reduced 5 mg dose: still 16.6 percent below starting weight, holding most of the result.
- Stopped (placebo): back to 9.9 percent below starting weight, and that flatters the picture, because two thirds of this group regained so much that the trial restarted their medication under its rescue rule. Only 8 percent of the full-dose group and 25 percent of the reduced-dose group needed rescue.
Cholesterol, blood pressure and blood sugar improvements held in the treated groups and deteriorated with regain. Earlier trials had already shown the two ends of this spectrum, continuing works and stopping leads to regain for most people; SURMOUNT-MAINTAIN filled in the middle: a reduced dose preserves most of the benefit.
The formal trial used tirzepatide, but the principle, that maintenance needs less support than weight loss, matches long-standing clinical experience across these medicines, including semaglutide. Your own maintenance plan is always individual and belongs with your prescriber.
Weight loss and maintenance are different jobs
It helps to think of treatment as two phases with different goals:
- The weight loss phase: dose stepping up, appetite strongly suppressed, steady loss.
- The maintenance phase: the lowest dose that holds your weight, appetite present but manageable, food and strength habits doing more of the work, and a switch of focus from losing to living well at your new weight.
Reaching goal weight is the transition between them, not the finish line. Obesity is a chronic condition; what changes at goal weight is the strategy, not the diagnosis.
How we approach dose reduction
Every plan is individual, but the guardrails we use look like this:
- Confirm you are actually ready. At goal weight, we review how you are eating (undereating is surprisingly common at high doses and is itself a reason to reduce), and often run blood tests to check nutrition, iron, vitamin D and general health before changing anything.
- Strengthen the foundations first. A maintenance diet is a different skill from a weight loss diet: more food, still protein-forward, still regular. This is a genuinely good moment for a session with a dietitian, and your protein and strength work matter more now, not less, because they are what hold your muscle and metabolism while the medication support lightens. See our guides to protein and strength training.
- Pick a calm season. Not Christmas, not mid-house-move, not during a family crisis. Stress and disrupted routines are when regain gets a foothold.
- Step down gradually, and slowly is fine. There is no prize for the fastest taper. Long, patient step-downs with reviews along the way are completely legitimate, and the pace is set with your prescriber.
- Have a wobble plan. If hunger surges or weight starts climbing after a reduction, the answer is simple and shame-free: step back up, steady, and try again later. The trial's own design worked this way, restarting treatment for people who regained. An adjustment is information, not failure.
The 3 kilogram rule
The single most protective habit in maintenance is reaching out early. Our rule of thumb: if you regain around 3 kilograms, get in touch. Not 10, not 15. Three.
Early regain is usually solvable, and often it is not even about the dose. Common findings at a 3 kg review: undereating that has slowed everything down, low iron or vitamin D, a rough patch of sleep, a stressful season, a new medication, or a habit drift that a food diary makes obvious. Sometimes the dose does need a nudge. Catching it at 3 kg means small corrections; waiting turns it into a restart.
Keep score on more than the scale
In maintenance, the scale is one instrument in the dashboard, and not the most important one. Waist measurement, how your clothes fit, strength, energy, sleep quality, blood pressure and blood results tell you whether your new weight is doing its real job: a healthier, more capable life. That is the outcome the evidence says continued treatment protects, and it is the one worth organising your plan around.
For the full picture of the habits behind lasting results, see Getting the best results on Wegovy or Mounjaro, and for what happens with stopping altogether, see Why weight loss medication is long-term treatment.
This article is general information, not personal medical advice. Never adjust your dose on your own; maintenance planning is something we do together.
Existing members: at or near your goal weight? Log in at member.wellrevolution.com and start a priority chat about your maintenance plan.
New to Well Revolution? Start an online weight management assessment with one of our NZ-registered doctors.
References
- Horn DB, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. Published online 12 May 2026. Link
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. Link
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. Link
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28:2083-2091. Link
- Rubino F, et al. Definition and diagnostic criteria of clinical obesity. The Lancet Diabetes and Endocrinology. 2025;13(3):221-262. Link
Seeing a doctor is as easy as sending a text
Concerned, need advice, a prescription, refill or referral?
Chat with a GP now
Subscribe to our newsletter
